Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM
(dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy
in patients with relapsed/refractory aggressive and indolent lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Georg Hess, MD
Collaborators:
Department of Hematology Krankenhaus Höchst Frankfurt Klinikum Frankfurt Höchst Roche Pharma AG